Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.410
-0.080 (-1.78%)
Mar 24, 2026, 1:12 PM EDT - Market open
Aptevo Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Aptevo Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Aptevo Therapeutics.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $199,800 → $106,560 | Strong Buy | Maintains | $199,800 → $106,560 | +2,416,226.53% | Sep 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $40,439,520 → $11,721,600 | Buy | Maintains | $40,439,520 → $11,721,600 | +265,795,818.37% | May 13, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $37,509,120 → $29,304,000 | Strong Buy | Maintains | $37,509,120 → $29,304,000 | +664,489,695.92% | May 28, 2021 |
| Piper Sandler | Piper Sandler | Buy Maintains $18,754,560 → $40,439,520 | Buy | Maintains | $18,754,560 → $40,439,520 | +916,995,818.37% | Nov 11, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $98,461,440 | Strong Buy | Initiates | $98,461,440 | +2,232,685,614.29% | Apr 11, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-98.85
EPS Next Year
-29.45
from -98.85
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -101.76 | -30.31 | ||||
| Avg | -98.85 | -29.45 | ||||
| Low | -94.97 | -28.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.